Peptide · Growth-hormone-releasing hormone (GHRH) analogue
CJC-1295
A modified analogue of growth-hormone-releasing hormone, developed pharmaceutically and never approved; often sold paired with ipamorelin.
No human authorisationSold for research. No regulator has authorised it for people.
- Legal status · US
- No human authorisation
- Evidence in people
- Molecule
- Growth-hormone-releasing hormone (GHRH) analogue
- In sport
- Prohibited (WADA)
- Status checked
Regulatory status · United States
No marketing authorisation anywhere, and not on the 503A Bulks List. The FDA lists its compounding nomination as withdrawn.
Prohibited at all times under WADA class S2 (growth-hormone-releasing factors).
What changed, and when
Shown by the FDA among nominations withdrawn for 503A.
What to be careful about
The "CJC/ipamorelin" pairing is a vendor product, not a studied combination. Neither component is an authorised medicine.
Why there is no dosing information here
There is no authorised human dose to report. Any figure printed here would come from a vendor or a forum, and would look exactly like one taken from an approved label — which is the specific confusion that makes this category dangerous.
Sources
- FDA — bulk drug substances that may present significant safety risks (Category 2), page current as of 22 April 2026
- WADA Prohibited List
Regulatory positions change. This page states the date it describes, and nothing on it is legal or medical advice.